Tesamorelin: The One With an Approved Indication

The short version

Tesamorelin is a chemically modified, longer-lasting version of the full natural growth hormone-releasing hormone (GHRH) — the signal that tells the pituitary gland to release the body's own growth hormone. Of the three peptides on this desk, it is the only one currently approved by the FDA, and the approval is specific: reducing excess abdominal fat in people living with HIV who have a fat-redistribution condition called lipodystrophy, a side effect of certain antiretroviral treatments.

Because it went through a full randomized, placebo-controlled trial program to earn that approval, tesamorelin has the deepest and most rigorous evidence base of any compound on this site. That evidence, though, is specific to the population and condition it was tested in — it does not automatically generalize to general fat loss, anti-aging use, or growth-hormone-axis support in people without lipodystrophy. This page describes exactly what was studied, in whom, and what the trials found.

What it is

Tesamorelin is a synthetic 44-amino-acid analogue of the full-length human growth hormone-releasing hormone, GHRH(1-44)-NH2, distinguished by a trans-3-hexenoic acid group conjugated to its N-terminus. That modification confers resistance to cleavage by the enzyme dipeptidyl peptidase-IV (DPP-IV), which otherwise rapidly degrades natural GHRH in plasma — extending tesamorelin's stability and effective duration relative to the unmodified hormone. The molecular formula of the free base is C221H366N72O67S; it is supplied clinically as the acetate salt. Unlike sermorelin, which is only the minimal 1-29 fragment, tesamorelin retains the full 44-residue GHRH sequence with this single stabilizing modification.

How it works

Tesamorelin binds the growth hormone-releasing hormone receptor on anterior-pituitary somatotroph cells, activating the Gs/adenylyl-cyclase/cAMP/protein-kinase-A cascade to stimulate synthesis and pulsatile secretion of endogenous growth hormone. The resulting GH drives hepatic production of insulin-like growth factor-1 (IGF-1), and together GH and IGF-1 promote lipolysis — the breakdown of stored fat — with a documented preference for visceral (deep abdominal) fat over other fat depots. Because tesamorelin amplifies the body's own pulsatile GH rhythm rather than supplying exogenous GH directly, its metabolic profile in trials has differed in important ways from recombinant GH therapy, particularly around glucose handling ^[15].

What the research shows

Meta-analytic evidence. A 2026 meta-analysis pooling five randomized controlled trials of tesamorelin in HIV-associated lipodystrophy found significant reductions in visceral adipose tissue (mean difference -27.71 cm2), trunk fat (-1.18 kg), and hepatic fat fraction (-4.28%), alongside an increase in lean body mass (+1.42 kg) — all statistically significant, with no serious adverse events reported across the pooled trials ^[1].

Regulatory history and liver safety. Tesamorelin was approved in the United States in 2010 specifically to reduce excess abdominal fat in HIV-infected patients with antiretroviral-related lipodystrophy. A federal drug-safety monograph assigns it a likelihood score of E — meaning it is an unlikely cause of clinically apparent liver injury — noting no reported attributable liver-injury cases and no new serum-enzyme elevations across its clinical trials ^[13].

Pivotal trial. In a six-month randomized trial of 50 antiretroviral-treated adults with HIV (28 on tesamorelin, 22 on placebo), tesamorelin 2 mg/day produced a treatment effect of -42 cm2 in visceral fat and reduced hepatic lipid content by a net -2.9% ^[14].

Mechanism in healthy men. In 13 healthy men, two weeks of tesamorelin 2 mg/day increased mean overnight GH and raised IGF-1 substantially, while neither fasting glucose nor insulin-stimulated glucose uptake was significantly affected — an early signal that the effect on insulin sensitivity is more limited than with direct GH administration ^[15].

Long-term data. Across a 52-week program (273 on tesamorelin, 137 on placebo), the visceral-fat reduction was sustained at -18% versus baseline, though fat reaccumulated after discontinuation, and glucose parameter changes over the full year were not clinically significant ^[16].

Reported effects, cautions & safety

Unlike the other two peptides on this desk, tesamorelin does not have an established base of research-community anecdotal reports in the literature this site tracks. Its studied use has been concentrated almost entirely in formal randomized trials and prescribing for a specific medical indication, not broad off-label community self-administration — so this section moves directly to the cited clinical safety record rather than an anecdotal layer that does not meaningfully exist for this compound.

Cited cautions from the clinical literature: Tesamorelin's FDA approval covers only reducing excess abdominal fat in HIV-associated lipodystrophy; every other proposed use — general visceral-fat reduction, anti-aging, cognitive enhancement, non-HIV fatty liver disease — is off-label and investigational, not covered by the approval trials described above. Visceral fat reaccumulates within weeks of stopping treatment, so any benefit observed in trials was contingent on continued dosing, not a one-time or curative effect ^[16]. Because GH-axis stimulation raises IGF-1, a growth factor, and because the pivotal trials showed no excess malignancy signal only over 52 weeks, long-term oncologic safety remains an open question, and active malignancy is a labeled contraindication. Modest glucose perturbation can occur in some individuals, though the dedicated healthy-volunteer study found no significant change in fasting glucose or insulin-stimulated glucose uptake ^[15], and the 52-week program likewise found no clinically significant glucose change ^[16]. Cognitive findings across the wider GHRH-analogue literature are mixed: one trial in an aging (non-HIV) population showed a favorable executive-function effect ^[7], while a separate, more recent trial in HIV-positive patients did not replicate a significant cognitive benefit. Tesamorelin is also a GHRH analogue prohibited in sport under anti-doping rules.

Where it fits in Growth Hormone Axis

Tesamorelin is the regulatory and evidentiary benchmark on this desk — the only compound with an actual FDA-approved indication and a genuine randomized, placebo-controlled trial program behind it ^[1][14][16]. That rigor is real but narrow: it applies to a specific population (HIV-associated lipodystrophy), not to sermorelin's broader historical pediatric-deficiency use or CJC-1295/Ipamorelin's combination-secretagogue approach. Reading all three together shows a genuine trade-off: the compound with the strongest trial evidence also has the narrowest studied population, while the compounds studied more broadly in research-use communities have thinner controlled-trial support. See the comparison page for the side-by-side.